Financial Performance - The company achieved an operating revenue of 925 million RMB, representing an 18.18% increase compared to the previous year [3] - The comprehensive gross profit margin was 71.31%, an increase of 1.09 percentage points year-on-year [3] - The adjusted net profit attributable to the parent company was approximately 182 million RMB, meeting the budget target for the year [3] Business Strategy - The company implemented a "3+2" market development strategy focusing on three key industries: peptides, bispecific antibodies/ADC, and blood products, while also exploring opportunities in vaccines and small nucleic acids [4] - Sales revenue from core business products, chromatography fillers and media, reached 552 million RMB, a growth of 22.57% year-on-year [4] - International business revenue was approximately 84 million RMB, showing a significant growth of about 78% [4] Research and Development - The company increased its R&D investment to 197 million RMB, an 11.12% increase from the previous year, accounting for 21.29% of the annual operating revenue [5] Profitability Improvement - Operating profit and total profit increased by 88.48% and 87.51% respectively, outpacing the growth rate of operating revenue [7] - The net profit attributable to the parent company grew by 64.18%, while the net profit excluding non-recurring gains and losses increased by 78.55% [7]